A study led by researchers from MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
Gabriele Casirati, of Boston Children’s Hospital, Susan E. De Wolf, of Memorial Sloan Kettering Cancer Center, Stephen Persaud, of Washington University School of Medicine, and Abdur Rehman, of the University of Texas MD Anderson Cancer Center, were awarded DKMS’ research grant in honor of John A. Hansen.
